JP: not just MANF and Phenoguard. They would also have Eltoprazine and ESS. My gut tells me they are not going to sell the diagnostics division. They buy assets and build their value for future monetization. Most of them are still early and could be developed for more value. I could see a sale of Lympro, but why. The actions of AMBS building out their Alzheimers Biomarkers via Georgetown and 'cornering' the Alzheimers Diagnostics market is an awesome long term strategy that suggests just that, long term. I could see a Lympro sale but I could see a large equity diagnostics partner or Lympro partner coming on board that would light the fire for an uplist. That would both get a large sum of money up front with the promise of continued revenue.
JP: not just MANF and Phenoguard. They would also have
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Exploring Advances in AI and Digital R&D Innovation by ICON plc
Recent Developments in AI and Digital Innovation by ICON plc ICON plc, a globally recognized clinical research organization (NASDAQ: ICLR), has recently conducted an extensive survey exploring the integration of Artificial Intelligence (AI) and digital tools within clinical research. Engaging with over 100 professionals in the biotech and pharmaceutical industries across...
Continue Reading
Tesla's Self-Driving Claims Under Fire: Industry Reactions
Tesla's License Suspension in California Recently, a court in California announced a significant development affecting Tesla Inc. (NASDAQ: TSLA). The court decided to suspend Tesla's license to sell vehicles for 30 days due to a lawsuit concerning misleading claims about the company's Full Self-Driving (FSD) technology. If Tesla does not adapt its policies within 90 days,...
Continue Reading
Sunnova Energy Faces Challenges Amid Revenue Declines in 2024
Sunnova Energy Experiences Financial Struggles Sunnova Energy International Inc. (NOVA) has encountered a challenging period, with its shares trading lower in the premarket on Monday following a disappointing report detailing its fourth quarter and full-year financial results. The financial landscape for Sunnova shows a revenue of $224.127 million, which unfortunately...
Continue Reading
Kerusso's Important Contributions in Faith and Community Work
Kerusso's Inspiring Charitable Contributions in 2025 Kerusso Activewear, a prominent Christian apparel and gift brand, has ended the year with a remarkable achievement of over $400,000 in charitable contributions. This reflects their steadfast commitment to enriching lives through faith-based approaches and generous support for individuals in need. Growing Demand for...
Continue Reading
Prelude Therapeutics and Incyte Join Forces for JAK2JH2 Inhibitor
Prelude Therapeutics Partners with Incyte on JAK2V617F Program Incyte establishes exclusive option to acquire Prelude’s innovative programs These inhibitors have the potential to modify disease outcomes in patients with myeloproliferative neoplasms (MPNs) Prelude Therapeutics, a clinical-stage oncology company, has recently made headlines with an exciting announcement...
Continue Reading